Cologuard, the first stool-based CRC screening test approved by the US Food and Drug Administration (FDA) with relatively high sensitivity and specificity, includes hemoglobin, multiple genetic mutations, and BMP3 and NDRG4 methylation sites as biomarkers (8). The gene discussed is BMP3; the disease is colorectal carcinoma.